Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

0.6 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe [Arixtra]

Known as: FONDAPARINUX SODIUM 7.5 mg in 0.6 mL SUBCUTANEOUS INJECTION, SOLUTION [ARIXTRA], 0.6 ML Arixtra 12.5 MG/ML Prefilled Syringe, Arixtra 7.5 MG in 0.6 ML Prefilled Syringe 
 
National Institutes of Health

Related topics

Related topics

6 relations
ArixtraFondaparinux sodiumPrefilled SyringeSodium Chloride
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Advancing MSn spatial resolution and documentation for glycosaminoglycans by sulfate-isotope exchange
Glycosaminoglycans (GAGs) are carbohydrate polyionic polymers that participate in a host of critically important biological… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
2015
2015
Investigating changes in the gas-phase conformation of Antithrombin III upon binding of Arixtra using traveling wave ion mobility spectrometry (TWIMS).
We validate the utility of ion mobility to measure protein conformational changes induced by the binding of glycosaminoglycan… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
A closer look at the nitrogen next door: 1H-15N NMR methods for glycosaminoglycan structural characterization.
Recently, experimental conditions were presented for the detection of the N-sulfoglucosamine (GlcNS) NHSO(3)(-) or sulfamate (1)H… Expand
2012
2012
Fondaparinux Sodium
SummaryAbstractFondaparinux sodium (Arixtra®; fondaparinux) is the first of a new class of synthetic pentasaccharide… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV
2010
2010
Intérêt du fondaparinux (Arixtra®) en hémodialyse dans les thrombopénies induites par l’héparine de type II (TIH II). À propos d’une nouvelle observation
Resume La thrombopenie induite par l’heparine de type II (TIH II) voit sa prise en charge s’enrichir regulierement d… Expand
2009
2009
An Ion Mobility-Mass Spectrometry Investigation of Monocyte Chemoattractant Protein-1.
In the present article we describe the gas-phase dissociation behavior of the dimeric form of monocyte chemoattractant protein-1… Expand
2004
2004
Le pentasaccharide (fondaparinux sodium, Arixtra ® ) : avantage à la synthèse ?
Auteur(s) :, Roger Cariou* Departement therapeutique thrombose, Sanofi Synthelabo Recherche, 91385 Chilly Mazarin cedex, France… Expand
2004
2004
Initial Outpatient Treatment of Venous Thromboembolism with Fondaparinux (Arixtra®): The Matisse Trials.
Background: The MATISSE trials showed that a single dose regimen of fondaparinux, a synthetic selective factor Xa inhibitor, was… Expand
2002
2002
Fondaparinux (Arixtra), a new anticoagulant.
  • P. Giangrande
  • The Medical letter on drugs and therapeutics
  • 2002
    • Corpus ID: 2714295
Fondaparinux is a promising new antithrombotic agent. This pentasaccharide selectively and specifically inhibits coagulation… Expand
2002
2002
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
Fondaparinux (Arixtra®; Sanofi-Synthélabo/Organon) is the first of a new class of antithrombotic agents distinct from low… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE